Document is current
Any future updates will be listed below
-
Authors
Tan, Harold Nathan https://orcid.org/0000-0003-3432-3062
Morcillo, Marta Ascanio
Lopez, Juanita
Minchom, Anna
Sharp, Adam
Paschalis, Alec
Silva-Fortes, Georgina
Raobaikady, Bindu
Banerji, Udai
- License Information
-
More Information
Article History
Received: 5 March 2025
Accepted: 17 June 2025
First Online: 3 July 2025
Declarations
:
: Ethical approval to collect, anonymize, and tabulate toxicities caused by ADCs on phase I trials was approved by the Committee for Clinical Research of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation trust; SE1324. The study was performed in accordance with the Declaration of Helsinki.
: HNT, MAM, GSF, BR have no conflicts of interest to declare. UB has attended advisory boards and been compensated by Ellipsis Pharma, PharmEnable, and Carrick Therapeutics. He has received preclinical research funding from Verastem and Avacta and research funding to run academic trials from Verastem, Chugai, BTG phamaceuticals and Carrick Therapeutics. JL has served as consultant or an advisory role for Genmab, Novartis, Basilea, Roche-Genentech, CureTeq, Ellipses Pharma, Pierre Fabre and GSK. She has received grant/research funding from Astex Pharmaceuticals, Basilea, and Roche-Genentech. She has received travel support from Basilea and Roche-Genentech. A.M. has served on advisory boards for Janssen, Merck, Takeda, MSD, Genmab, Merck, Pfizer, Astrazaneca and Immutep. She has received honoraria from Chugai, Faron, Merck, GSK, Seagen, Takeda and Janssen. A.M has received travel support from Amgen and Janssen. She has received research funding from Astex, Merck and MSD. A. S. is an employee of the ICR, which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers, and PI3K/AKT pathway inhibitors (no personal income). A.S. has received travel support from Sanofi, Roche-Genentech and Nurix, and speaker honoraria from Astellas Pharma and Merck Sharp & Dohme. He has served as an advisor to DE Shaw Research, CHARM Therapeutics, Ellipses Pharma and Droia Ventures. A. S. has been the CI/PI of industry-sponsored clinical trials. A.P. is named on a patent held by the Institute of Cancer Research (ICR) together with Cancer Research UK identifying JMJD6 as a therapeutic target in advanced prostate cancer.
